• Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 117.82%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.05
▲ +0.08 (1.61%)

This chart shows the closing price for KMDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kamada Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KMDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KMDA

Analyst Price Target is $11.00
▲ +117.82% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Kamada in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 117.82% upside from the last price of $5.05.

This chart shows the closing price for KMDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Kamada. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00N/A
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
8/17/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
3/16/2023HC WainwrightReiterated RatingBuy$11.00Low
11/23/2021HC WainwrightReiterated RatingBuyLow
8/14/2020Chardan CapitalBoost TargetPositive ➝ Buy$7.00 ➝ $11.00High
8/13/2020HC WainwrightReiterated RatingBuy$11.00Low
5/19/2020HC WainwrightReiterated RatingBuy$11.00High
12/23/2019HC WainwrightReiterated RatingBuy$11.00Medium
8/7/2019HC WainwrightReiterated RatingBuy$11.00Low
(Data available from 6/25/2019 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/27/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/26/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2024

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Kamada logo
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $5.05
Low: $4.92
High: $5.07

50 Day Range

MA: $5.27
Low: $4.78
High: $5.75

52 Week Range

Now: $5.05
Low: $4.08
High: $6.53

Volume

17,672 shs

Average Volume

20,768 shs

Market Capitalization

$290.27 million

P/E Ratio

21.96

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Kamada?

The following Wall Street analysts have issued stock ratings on Kamada in the last twelve months: HC Wainwright, StockNews.com, and TheStreet.
View the latest analyst ratings for KMDA.

What is the current price target for Kamada?

1 Wall Street analysts have set twelve-month price targets for Kamada in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 117.8%. HC Wainwright has the highest price target set, predicting KMDA will reach $11.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Kamada in the next year.
View the latest price targets for KMDA.

What is the current consensus analyst rating for Kamada?

Kamada currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KMDA will outperform the market and that investors should add to their positions of Kamada.
View the latest ratings for KMDA.

What other companies compete with Kamada?

How do I contact Kamada's investor relations team?

Kamada's physical mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company's listed phone number is (728) 940-6472 and its investor relations email address is [email protected]. The official website for Kamada is www.kamada.com. Learn More about contacing Kamada investor relations.